Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения
Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения
Чернуха Г.Е. Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения. Гинекология. 2024;26(3):260–269. DOI: 10.26442/20795696.2024.3.202894
Chernukha GE. Heavy menstrual bleeding and anemia: The problem is growing and requires a solution. A review. Gynecology. 2024;26(3):260–269. DOI: 10.26442/20795696.2024.3.202894
Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения
Чернуха Г.Е. Обильные менструальные кровотечения и анемия: проблема нарастает и требует решения. Гинекология. 2024;26(3):260–269. DOI: 10.26442/20795696.2024.3.202894
Chernukha GE. Heavy menstrual bleeding and anemia: The problem is growing and requires a solution. A review. Gynecology. 2024;26(3):260–269. DOI: 10.26442/20795696.2024.3.202894
Анемия – одна из глобальных проблем здравоохранения, затрагивающая около 1/4 мирового населения, особенно женщин репродуктивного возраста и детей раннего возраста. В 50–75% случаев анемия является вторичной по отношению к железодефициту (ЖД). Несмотря на высокую распространенность обильных менструальных кровотечений (ОМК), связанные с ними железодефицитные расстройства недооцениваются, хотя резко снижают качество жизни и несут значительные риски для матери, плода и новорожденного в случае наступления беременности. С этой целью рекомендуется рутинный скрининг девушек и женщин репродуктивного возраста на наличие ЖД и анемии. Новая инициатива FIGO призвана повысить осведомленность женщин и клиницистов о взаимосвязи ОМК и железодефицитных состояний. Ключевое значение имеют: ранняя диагностика ОМК, устранение возможной причины, выявление связанных с ней железодефицитных нарушений, особенно доклинических форм. Главной задачей гинеколога является назначение терапии, направленной на быстрое прекращение высоких ежемесячных потерь железа и восполнение имеющегося ЖД. Согласно Российским клиническим рекомендациям комбинированные оральные контрацептивы и внутриматочная система с левоноргестрелом относятся к терапии 1-й линии для снижения объема менструальной кровопотери у пациенток с ОМК, нуждающихся в контрацепции. Препараты Клайра® и Мирена® являются единственными гормональными препаратами, зарегистрированными для контрацепции и лечения ОМК, не связанных со структурными нарушениями матки, поскольку их значительный эффект в снижении менструальной кровопотери, восстановлении уровней гемоглобина и ферритина подтвержден в исследованиях с высоким уровнем доказательности.
Ключевые слова: обильное менструальное кровотечение, дефицит железа, железодефицитная анемия, качество жизни, менструальная кровопотеря, ферритин, комбинированный оральный контрацептив, эстрадиола валерат/диеногест, внутриматочная система с левоноргестрелом
________________________________________________
Anemia is a global health problem, affecting about a quarter of the world's population, especially women of reproductive age and young children. In 50–75% of cases, anemia is secondary to iron deficiency (ID). Despite the high prevalence of heavy menstrual bleeding (HMB), the associated iron deficiency disorders are underestimated, although they sharply reduce the quality of life and carry significant risks for the mother, fetus and newborn in case of pregnancy. For this purpose, routine screening of girls and women of reproductive age for the presence of ID and anemia is recommended. The new FIGO initiative aims to raise awareness among women and clinicians about the relationship between HMB and ID conditions. Of key importance are: early diagnosis of HMB, elimination of the possible cause, identification of associated iron deficiency disorders, especially preclinical forms. The main task of the gynecologist is to prescribe therapy aimed at quickly stopping high monthly iron losses and replenishing the existing ID. According to Russian clinical guidelines, combined oral contraceptives and an intrauterine system with levonorgestrel are considered first-line therapy to reduce the volume of menstrual blood loss in patients with HMB who require contraception. Qlaira® and Mirena® are the only hormonal drugs registered for contraception and the treatment of HMB not associated with structural disorders of the uterus, since their high effectiveness in reducing menstrual blood loss, restoring hemoglobin and ferritin levels has been confirmed in studies with a high level of evidence.
Keywords: heavy menstrual bleeding, iron deficiency, iron deficiency anemia, quality of life, menstrual blood loss, ferritin, combined oral contraceptive, estradiol valerate/dienogest, levonorgestrel-releasing intrauterine system
1. WHO. The Global Prevalence of Anaemia in 2011. WHO. Accessed July 1, 2019. Available at: https://iris.who.int/bitstream/handle/10665/177094/9789241564960_eng.pdf. Accessed: 01.07.2024.
2. Баранов И.И., Сальникова И.А., Нестерова Л.А. Клинические рекомендации по диагностике и лечению железодефицитных состояний: взгляд из 2022 г. Акушерство и гинекология: новости, мнения, обучение. 2022;10(2):56-64 [Baranov II, Salnikova IA, Nesterova LA. Clinical practice guidelines for the diagnosis and treatment of iron deficiency: the view from 2022. Obstetrics and Gynecology: News, Opinions, Training. 2022;10(2):56-64 (in Russian)]. DOI:10.33029/2303-9698-2022-10-2-56-64
3. International Federation of Gynecology and Obstetrics. FIGO Statement: Iron deficiency and anaemia in women and girls. 2023. Available at: www.figo.org/resources/figo-statements/iron-deficiency-and-anaemia-women-and-girls. Accessed: 01.07.2024.
4. Williams AM, Addo OY, Grosse SD, et al. Data needed to respond appropriately to anemia when it is a public health problem. Ann NY Acad Sci. 2019;1450(1):268-80. DOI:10.1111/nyas.14175
5. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci. 2019;1450(1):15-31. DOI:10.1111/nyas.14092
6. Аномальные маточные кровотечения. Клинические рекомендации Российского общества акушеров-гинекологов (РОАГ). 2021 [Anomal'nye matochnye krovotecheniia. Klinicheskie rekomendatsii Rossiiskogo obshchestva akusherov-ginekologov (ROAG). 2021 (in Russian)].
7. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Obstet Gynecol. 2018;143(3):393-408. DOI:10.1002/ijgo.12666
8. Munro MG, Mast AE, Powers JM, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1-9. DOI:10.1016/j.ajog.2023.01.017
9. Kocaoz S, Cirpan R, Degirmencioglu AZ. The prevalence and impacts heavy menstrual bleeding on anemia, fatigue and quality of life in women of reproductive age. Pak J Med Sci. 2019;35(2):365-70. DOI:10.12669/pjms.35.2.644
10. Романов А.Ю., Солдатова Е.Е., Гаджиева А.Р., Кесова М.И. Профилактика железодефицитной анемии при беременности и лактации. Медицинский совет. 2020;(3):85-9 [Romanov AY, Soldatova EE, Gadzhieva AR, Kesova MI. Prevention of iron deficiency anemia in pregnancy and lactation. Medical Council. 2020;(3):85-9 (in Russian)].
DOI:10.21518/2079-701X-2020-3-85-89
11. Wiegersma AM, Dalman C, Lee BK, et al. Association of prenatal maternal anemia with neurodevelopmental disorders. JAMA Psychiatry. 2019;76(12):1294-304. DOI:10.1001/jamapsychiatry.2019.2309
12. Janbek J, Sarki M, Specht IO, Heitmann BL. A systematic literature review of the relation between iron status/anemia in pregnancy and offspring neurodevelopment. Eur J Clin Nutr. 2019;73(12):1561-78. DOI:10.1038/s41430-019-0400-6
13. Резолюция совета экспертов по железодефицитной анемии у женщин. Акушерство и гинекология: новости, мнения, обучение. 2020;8(4):28-36 [Expert council resolution on iron-deficiency anemia in women. Obstetrics and Gynecology: News, Opinions, Training. 2020;8(4):28-36 (in Russian)]. DOI:10.24411/2303-9698-2020-14004
14. National Institute of Health and Care Excellence. Heavy menstrual bleeding: assessment and management. NICE guideline. 2018. Last updated: 24 May 2021. Available at: https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-p.... Accessed: 01.07.2024.
15. Shimamoto K, Hirano M, Wada-Hiraike O, et al. Examining the association between menstrual symptoms and health related quality of life among working women in Japan using the EQ-5D. BMC Womens Health. 2021;21(1):325. DOI:10.1186/s12905-021-01462-7
16. Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9(6):e026186. DOI:10.1136/bmjopen-2018-026186
17. Schoep ME, Nieboer TE, van der Zanden M, et al. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol. 2019;220(6):569e1-7. DOI:10.1016/j.ajog.2019.02.048
18. Munro MG. Abnormal uterine bleeding: A well-travelled path to iron deficiency and anemia. Int J Gynecol Obstet. 2020;150(3):275-7. DOI:10.1002/ijgo.13180
19. Da Silva Filho AL, Caetano C, Lahav A, et al. The difficult journey to treatment for women suffering from heavy menstrual bleeding: a multinational survey. Eur J Contracept Reprod Health Care. 2021;26(5):390-8. DOI:10.1080/13625187.2021.1925881
20. Mansour D, Hofmann A, Gemzell-Danielsson K. A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding. Adv Ther. 2021;38(1):201-25. DOI:10.1007/s12325-020-01564-y
21. Железодефицитная анемия. Клинические рекомендации. 2021. [Zhelezodefitsitnaia anemiia. Klinicheskie rekomendatsii. 2021 (in Russian)].
22. Dugan C, MacLean B, Cabolis K, et al. The misogyny of iron deficiency. Anaesthesia. 2021;76(Suppl. 4):56-62. DOI:10.1111/anae.1543224
23. Beckert RH, Baer RJ, Anderson JG, et al. Maternal anemia and pregnancy outcomes: a population-based study. J Perinatol. 2019;39(7):911-9. DOI:10.1038/s41372-019-0375-0
24. Adam I, Salih Y, Hamdan HZ. Association of Maternal Anemia and Cesarean Delivery: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(2):490. DOI:10.3390/jcm12020490
25. Ardic C, Usta O, Omar E, et al. Relationship between anaemia during pregnancy and preterm delivery. J Obstet Gynaecol. 2019;39(7):903-6. DOI:10.1080/01443615.2019.1572726
26. Azami M, Badfar G, Khalighi Z, et al. The association between anemia and postpartum depression: A systematic review and meta-analysis. Caspian J Intern Med. 2019;10(2):115-24. DOI:10.22088/cjim.10.2.115
27. Bailey RL, West KP Jr, Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab. 2015;66(Suppl. 2):22-33. DOI:10.1159/000371618
28. Moos T, Skjørringe T, Thomsen LL. Iron deficiency and iron treatment in the fetal developing brain – a pilot study introducing an experimental rat model. Reprod Health. 2018;15(Suppl. 1):93. DOI:10.1186/s12978-018-0537-0
29. Ших Е.В., Бриль Ю.А. Железодефицит: катастрофа для нейрогенеза. StatusPraesens. 2018;5:82-8 [Shikh EV, Bril' IuA. Zhelezodefitsit: katastrofa dlia neirogeneza. StatusPraesens. 2018;5:82-8 (in Russian)].
30. Виноградова М.А. Анемия у женщин репродуктивного возраста: диагностика и коррекция железодефицита. Акушерство и гинекология. 2019;6:140-5 [Vinogradova MA. Anemia in reproductive-aged women: diagnosis and correction of iron deficiency. Obstetrics and Gynegology. 2019;6:140-5 (in Russian)]. DOI:10.18565/aig.2019.6.140-145
31. Georgieff MK. The importance of iron deficiency in pregnancy on fetal, neonatal, and infant neurodevelopmental outcomes. Int J Gynaecol Obstet. 2023;162(Suppl. 2):83-8. DOI:10.1002/ijgo.14951
32. Oh C, Keats EC, Bhutta ZA. Vitamin and mineral supplementation during pregnancy on maternal, birth, child health and development outcomes in low- and middle-income countries: a systematic review and meta-analysis. Nutrients. 2020;12(2):491. DOI:10.3390/nu12020491
33. Athe R, Dwivedi R, Pati S, et al. Meta-analysis approach on iron fortification and its effect on pregnancy and its outcome through randomized, controlled trials. J Fam Med Prim Care. 2020;9(2):513-9. DOI:10.4103/jfmpc.jfmpc_817_19
34. Daru J, Zamora J, Fernández-Félix BM, et al. Risk of maternal mortality in women with severe anaemia during pregnancy and postpartum: a multilevel analysis. Lancet Glob Health. 2018;6(5):e548-54. DOI:10.1016/S2214-109X(18)30078-04
35. Jung J, Rahman MM, Rahman MS, et al. Effects of hemoglobin levels during pregnancy on adverse maternal and infant outcomes: a systematic review and meta-analysis. Ann N Y Acad Sci. 2019;1450(1):69-82. DOI:10.1111/nyas.14112
36. Чернуха Г.Е. Актуальность проблемы аномальных маточных кровотечений у молодых женщин и ее комплексное решение в свете российских рекомендаций 2021. Гинекология. 2022;24(3):198-205 [Chernukha GE. Relevance of abnormal uterine bleeding issue in young women and its comprehensive solution considering 2021 Russian Guidelines. Gynecology. 2022;24(3):198-205 (in Russian)]. DOI:10.26442/20795696.2022.3.201683
37. Magnay JL, O’Brien S, Gerlinger C, Seitz C. Pictorial methods to assess heavy menstrual bleeding in research and clinical practice: a systematic literature review. BMC Womens Health. 2020;20(1):24. DOI:10.1186/s12905-020-0887-y
38. Singh SS, Calaf Alsina J, Vannuccini S, et al. Clinical perspectives on the menstrual pictogram for the assessment of heavy menstrual bleeding. Hum Reprod Open. 2022;2022(4):hoac048. DOI:10.1093/hropen/hoac048
39. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization, 2020. Available at: https://www.who.int/publications/i/item/9789240000124. Accessed: 01.07.2024.
40. Finkelstein JL, Fothergill A, Guetterman HM, et al. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022;49:483-94. DOI:10.1016/j.clnesp.2022.02.123
41. Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 2011;83(1):48-54. DOI:10.1016/j.contraception.2010.06.011
42. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol. 2010;116(4):865-75. DOI:10.1097/AOG.0b013e3181f20177
43. Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258-69. DOI:10.3109/13625187.2011.591456
44. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436-44. DOI:10.1016/j.contraception.2009.03.018
45. Fruzzetti F, Paoletti AM, Fidecicchi T, et al. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access J Contracept. 2019;10:1-6. DOI:10.2147/OAJC.S204655
46. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health.
2016;8:477-87. DOI:10.2147/IJWH.S107586
47. Андреева Е.Н., Шереметьева Е.В., Прилепская В.Н. Национальные медицинские критерии приемлемости методов контрацепции 2023: фокус на сохранение репродуктивного здоровья женщин. Гинекология. 2023;25(2):124-32 [Andreeva EN, Sheremetyeva EV, Prilepskaya VN. National medical eligibility criteria for contraceptive use 2023: focus on women's reproductive health: A review. Gynecology. 2023;25(2):124-32 (in Russian)]. DOI:10.26442/20795696.2023.2.202236
48. Прилепская В.Н., Андреева Е.Н. Удовлетворенность молодых женщин препаратом Э2В/ДНГ в реальной клинической практике в России: результаты проспективного многоцентрового наблюдательного исследования «Лебедь». Акушерство и гинекология. 2024;3:108-17 [Prilepskaya VN, Andreeva EN. Satisfaction of young women with estradiol valerate/dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN. Obstetrics and Gynecology. 2024;3:108-17 (in Russian)]. DOI:10.18565/aig.2024.21
49. Jensen JT, Bitzer J, Nappi RE, et al. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur J Contracept Reprod Health Care. 2020;25(2):98-105. DOI:10.1080/13625187.2020.1731734
50. Gemzell-Danielsson K, Kubba A, Caetano CF. Thirty years of Mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100:614-8. DOI:10.1111/aogs.14110
51. Agarwal M, Singh S, Sinha S, et al. Comparison of Bleeding Pattern and Quality of Life Before and After the Insertion of a Levonorgestrel Intrauterine System for Heavy Menstrual Bleeding: A Seven-Year Review. Cureus. 2023;15(3):36142. DOI:10.7759/cureus.36142
52. Chen BA, Eisenberg DL, Schreiber CA, et al. Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. Am J Obstet Gynecol. 2020;222(4S):S888.e1-6. DOI:10.1016/j.ajog.2019.11.1288
53. Beelen P, van den Brink MJ, Herman MC, et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding. Am J Obstet Gynecol. 2021;224(2):187.e1-10. DOI:10.1016/j.ajog.2020.08.016
54. Van den Brink MJ, Beelen P, Herman MC, et al. The levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding: a cost-effectiveness analysis. BJOG. 2021;128:2003-11. DOI:10.1111/1471-0528.16836
55. Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica. 2016;101:e6-7. DOI:10.3324/haematol.2015.129114
________________________________________________
1. WHO. The Global Prevalence of Anaemia in 2011. WHO. Accessed July 1, 2019. Available at: https://iris.who.int/bitstream/handle/10665/177094/9789241564960_eng.pdf. Accessed: 01.07.2024.
2. Baranov II, Salnikova IA, Nesterova LA. Clinical practice guidelines for the diagnosis and treatment of iron deficiency: the view from 2022. Obstetrics and Gynecology: News, Opinions, Training. 2022;10(2):56-64 (in Russian). DOI:10.33029/2303-9698-2022-10-2-56-64
3. International Federation of Gynecology and Obstetrics. FIGO Statement: Iron deficiency and anaemia in women and girls. 2023. Available at: www.figo.org/resources/figo-statements/iron-deficiency-and-anaemia-women-and-girls. Accessed: 01.07.2024.
4. Williams AM, Addo OY, Grosse SD, et al. Data needed to respond appropriately to anemia when it is a public health problem. Ann NY Acad Sci. 2019;1450(1):268-80. DOI:10.1111/nyas.14175
5. Chaparro CM, Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. Ann N Y Acad Sci. 2019;1450(1):15-31. DOI:10.1111/nyas.14092
6. Anomal'nye matochnye krovotecheniia. Klinicheskie rekomendatsii Rossiiskogo obshchestva akusherov-ginekologov (ROAG). 2021 (in Russian).
7. Munro MG, Critchley HOD, Fraser IS; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Obstet Gynecol. 2018;143(3):393-408. DOI:10.1002/ijgo.12666
8. Munro MG, Mast AE, Powers JM, et al. The relationship between heavy menstrual bleeding, iron deficiency, and iron deficiency anemia. Am J Obstet Gynecol. 2023;229(1):1-9. DOI:10.1016/j.ajog.2023.01.017
9. Kocaoz S, Cirpan R, Degirmencioglu AZ. The prevalence and impacts heavy menstrual bleeding on anemia, fatigue and quality of life in women of reproductive age. Pak J Med Sci. 2019;35(2):365-70. DOI:10.12669/pjms.35.2.644
10. Romanov AY, Soldatova EE, Gadzhieva AR, Kesova MI. Prevention of iron deficiency anemia in pregnancy and lactation. Medical Council. 2020;(3):85-9 (in Russian). DOI:10.21518/2079-701X-2020-3-85-89
11. Wiegersma AM, Dalman C, Lee BK, et al. Association of prenatal maternal anemia with neurodevelopmental disorders. JAMA Psychiatry. 2019;76(12):1294-304. DOI:10.1001/jamapsychiatry.2019.2309
12. Janbek J, Sarki M, Specht IO, Heitmann BL. A systematic literature review of the relation between iron status/anemia in pregnancy and offspring neurodevelopment. Eur J Clin Nutr. 2019;73(12):1561-78. DOI:10.1038/s41430-019-0400-6
13. Expert council resolution on iron-deficiency anemia in women. Obstetrics and Gynecology: News, Opinions, Training. 2020;8(4):28-36 (in Russian).
DOI:10.24411/2303-9698-2020-14004
14. National Institute of Health and Care Excellence. Heavy menstrual bleeding: assessment and management. NICE guideline. 2018. Last updated: 24 May 2021. Available at: https://www.nice.org.uk/guidance/ng88/resources/heavy-menstrual-bleeding-assessment-and-management-p.... Accessed: 01.07.2024.
15. Shimamoto K, Hirano M, Wada-Hiraike O, et al. Examining the association between menstrual symptoms and health related quality of life among working women in Japan using the EQ-5D. BMC Womens Health. 2021;21(1):325. DOI:10.1186/s12905-021-01462-7
16. Schoep ME, Adang EMM, Maas JWM, et al. Productivity loss due to menstruation-related symptoms: a nationwide cross-sectional survey among 32 748 women. BMJ Open. 2019;9(6):e026186. DOI:10.1136/bmjopen-2018-026186
17. Schoep ME, Nieboer TE, van der Zanden M, et al. The impact of menstrual symptoms on everyday life: a survey among 42,879 women. Am J Obstet Gynecol. 2019;220(6):569e1-7. DOI:10.1016/j.ajog.2019.02.048
18. Munro MG. Abnormal uterine bleeding: A well-travelled path to iron deficiency and anemia. Int J Gynecol Obstet. 2020;150(3):275-7. DOI:10.1002/ijgo.13180
19. Da Silva Filho AL, Caetano C, Lahav A, et al. The difficult journey to treatment for women suffering from heavy menstrual bleeding: a multinational survey. Eur J Contracept Reprod Health Care. 2021;26(5):390-8. DOI:10.1080/13625187.2021.1925881
20. Mansour D, Hofmann A, Gemzell-Danielsson K. A Review of Clinical Guidelines on the Management of Iron Deficiency and Iron-Deficiency Anemia in Women with Heavy Menstrual Bleeding. Adv Ther. 2021;38(1):201-25. DOI:10.1007/s12325-020-01564-y
21. Zhelezodefitsitnaia anemiia. Klinicheskie rekomendatsii. 2021 (in Russian).
22. Dugan C, MacLean B, Cabolis K, et al. The misogyny of iron deficiency. Anaesthesia. 2021;76(Suppl. 4):56-62. DOI:10.1111/anae.1543224
23. Beckert RH, Baer RJ, Anderson JG, et al. Maternal anemia and pregnancy outcomes: a population-based study. J Perinatol. 2019;39(7):911-9. DOI:10.1038/s41372-019-0375-0
24. Adam I, Salih Y, Hamdan HZ. Association of Maternal Anemia and Cesarean Delivery: A Systematic Review and Meta-Analysis. J Clin Med. 2023;12(2):490. DOI:10.3390/jcm12020490
25. Ardic C, Usta O, Omar E, et al. Relationship between anaemia during pregnancy and preterm delivery. J Obstet Gynaecol. 2019;39(7):903-6. DOI:10.1080/01443615.2019.1572726
26. Azami M, Badfar G, Khalighi Z, et al. The association between anemia and postpartum depression: A systematic review and meta-analysis. Caspian J Intern Med. 2019;10(2):115-24. DOI:10.22088/cjim.10.2.115
27. Bailey RL, West KP Jr, Black RE. The epidemiology of global micronutrient deficiencies. Ann Nutr Metab. 2015;66(Suppl. 2):22-33. DOI:10.1159/000371618
28. Moos T, Skjørringe T, Thomsen LL. Iron deficiency and iron treatment in the fetal developing brain – a pilot study introducing an experimental rat model. Reprod Health. 2018;15(Suppl. 1):93. DOI:10.1186/s12978-018-0537-0
29. Shikh EV, Bril' IuA. Zhelezodefitsit: katastrofa dlia neirogeneza. StatusPraesens. 2018;5:82-8 (in Russian).
30. Vinogradova MA. Anemia in reproductive-aged women: diagnosis and correction of iron deficiency. Obstetrics and Gynegology. 2019;6:140-5 (in Russian). DOI:10.18565/aig.2019.6.140-145
31. Georgieff MK. The importance of iron deficiency in pregnancy on fetal, neonatal, and infant neurodevelopmental outcomes. Int J Gynaecol Obstet. 2023;162(Suppl. 2):83-8. DOI:10.1002/ijgo.14951
32. Oh C, Keats EC, Bhutta ZA. Vitamin and mineral supplementation during pregnancy on maternal, birth, child health and development outcomes in low- and middle-income countries: a systematic review and meta-analysis. Nutrients. 2020;12(2):491. DOI:10.3390/nu12020491
33. Athe R, Dwivedi R, Pati S, et al. Meta-analysis approach on iron fortification and its effect on pregnancy and its outcome through randomized, controlled trials. J Fam Med Prim Care. 2020;9(2):513-9. DOI:10.4103/jfmpc.jfmpc_817_19
34. Daru J, Zamora J, Fernández-Félix BM, et al. Risk of maternal mortality in women with severe anaemia during pregnancy and postpartum: a multilevel analysis. Lancet Glob Health. 2018;6(5):e548-54. DOI:10.1016/S2214-109X(18)30078-04
35. Jung J, Rahman MM, Rahman MS, et al. Effects of hemoglobin levels during pregnancy on adverse maternal and infant outcomes: a systematic review and meta-analysis. Ann N Y Acad Sci. 2019;1450(1):69-82. DOI:10.1111/nyas.14112
36. Chernukha GE. Relevance of abnormal uterine bleeding issue in young women and its comprehensive solution considering 2021 Russian Guidelines. Gynecology. 2022;24(3):198-205 (in Russian). DOI:10.26442/20795696.2022.3.201683
37. Magnay JL, O’Brien S, Gerlinger C, Seitz C. Pictorial methods to assess heavy menstrual bleeding in research and clinical practice: a systematic literature review. BMC Womens Health. 2020;20(1):24. DOI:10.1186/s12905-020-0887-y
38. Singh SS, Calaf Alsina J, Vannuccini S, et al. Clinical perspectives on the menstrual pictogram for the assessment of heavy menstrual bleeding. Hum Reprod Open. 2022;2022(4):hoac048. DOI:10.1093/hropen/hoac048
39. WHO guideline on use of ferritin concentrations to assess iron status in individuals and populations. Geneva: World Health Organization, 2020. Available at: https://www.who.int/publications/i/item/9789240000124. Accessed: 01.07.2024.
40. Finkelstein JL, Fothergill A, Guetterman HM, et al. Iron status and inflammation in women of reproductive age: A population-based biomarker survey and clinical study. Clin Nutr ESPEN. 2022;49:483-94. DOI:10.1016/j.clnesp.2022.02.123
41. Shabaan MM, Zakherah MS, El-Nashar SA, Sayed GH. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 2011;83(1):48-54. DOI:10.1016/j.contraception.2010.06.011
42. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet Gynecol. 2010;116(4):865-75. DOI:10.1097/AOG.0b013e3181f20177
43. Fraser IS, Parke S, Mellinger U, et al. Effective treatment of heavy and/or prolonged menstrual bleeding without organic cause: pooled analysis of two multinational, randomised, double-blind, placebo-controlled trials of oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care. 2011;16(4):258-69. DOI:10.3109/13625187.2011.591456
44. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009;80(5):436-44. DOI:10.1016/j.contraception.2009.03.018
45. Fruzzetti F, Paoletti AM, Fidecicchi T, et al. Contraception with estradiol valerate and dienogest: adherence to the method. Open Access J Contracept. 2019;10:1-6. DOI:10.2147/OAJC.S204655
46. Briggs P, Serrani M, Vogtländer K, Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int J Womens Health.
2016;8:477-87. DOI:10.2147/IJWH.S107586
47. Andreeva EN, Sheremetyeva EV, Prilepskaya VN. National medical eligibility criteria for contraceptive use 2023: focus on women's reproductive health: A review. Gynecology. 2023;25(2):124-32 (in Russian). DOI:10.26442/20795696.2023.2.202236
48. Prilepskaya VN, Andreeva EN. Satisfaction of young women with estradiol valerate/dienogest in real clinical practice in Russia: results of prospective multicenter observational study Q-SWAN. Obstetrics and Gynecology. 2024;3:108-17 (in Russian). DOI:10.18565/aig.2024.21
49. Jensen JT, Bitzer J, Nappi RE, et al. Pooled analysis of bleeding profile, efficacy and safety of oral oestradiol valerate/dienogest in women aged 25 and under. Eur J Contracept Reprod Health Care. 2020;25(2):98-105. DOI:10.1080/13625187.2020.1731734
50. Gemzell-Danielsson K, Kubba A, Caetano CF. Thirty years of Mirena: a story of innovation and change in women’s healthcare. Acta Obstet Gynecol Scand. 2021;100:614-8. DOI:10.1111/aogs.14110
51. Agarwal M, Singh S, Sinha S, et al. Comparison of Bleeding Pattern and Quality of Life Before and After the Insertion of a Levonorgestrel Intrauterine System for Heavy Menstrual Bleeding: A Seven-Year Review. Cureus. 2023;15(3):36142. DOI:10.7759/cureus.36142
52. Chen BA, Eisenberg DL, Schreiber CA, et al. Bleeding changes after levonorgestrel 52-mg intrauterine system insertion for contraception in women with self-reported heavy menstrual bleeding. Am J Obstet Gynecol. 2020;222(4S):S888.e1-6. DOI:10.1016/j.ajog.2019.11.1288
53. Beelen P, van den Brink MJ, Herman MC, et al. Levonorgestrel-releasing intrauterine system versus endometrial ablation for heavy menstrual bleeding. Am J Obstet Gynecol. 2021;224(2):187.e1-10. DOI:10.1016/j.ajog.2020.08.016
54. Van den Brink MJ, Beelen P, Herman MC, et al. The levonorgestrel intrauterine system versus endometrial ablation for heavy menstrual bleeding: a cost-effectiveness analysis. BJOG. 2021;128:2003-11. DOI:10.1111/1471-0528.16836
55. Okam MM, Koch TA, Tran MH. Iron deficiency anemia treatment response to oral iron therapy: a pooled analysis of five randomized controlled trials. Haematologica. 2016;101:e6-7. DOI:10.3324/haematol.2015.129114
Авторы
Г.Е. Чернуха*
ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова» Минздрава России, Москва, Россия
*g_chernukha@oparina4.ru
________________________________________________
Galina E. Chernukha*
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Moscow, Russia
*g_chernukha@oparina4.ru